Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 25.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 424,797 shares of the specialty pharmaceutical company’s stock after purchasing an additional 85,529 shares during the quarter. Dimensional Fund Advisors LP’s holdings in ANI Pharmaceuticals were worth $22,297,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its stake in ANI Pharmaceuticals by 44.6% in the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 664 shares in the last quarter. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals in the third quarter worth approximately $197,000. Crossmark Global Holdings Inc. bought a new position in ANI Pharmaceuticals in the third quarter worth approximately $226,000. Stevens Capital Management LP bought a new position in ANI Pharmaceuticals in the second quarter worth approximately $207,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in ANI Pharmaceuticals in the second quarter worth approximately $210,000. 55.08% of the stock is currently owned by institutional investors.
Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) opened at $69.94 on Monday. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $815.01, a price-to-earnings ratio of 109.28 and a beta of 2.90. ANI Pharmaceuticals Inc has a twelve month low of $42.23 and a twelve month high of $74.70.
Several research analysts recently issued reports on ANIP shares. Canaccord Genuity reissued a “buy” rating and issued a $66.00 price objective (up previously from $60.00) on shares of ANI Pharmaceuticals in a research note on Monday, October 16th. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a report on Tuesday, November 7th. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Finally, BidaskClub lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $71.00.
COPYRIGHT VIOLATION NOTICE: This piece was published by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/ani-pharmaceuticals-inc-anip-shares-bought-by-dimensional-fund-advisors-lp/1852710.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.